Project Grant R01HL179205

Award Date 5/15/25
Completion Date 2/28/30
Dollars Obligated $639K
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
University City, MO 63130, USA
Similar Awards
This federal Project Grant award of $308,526.00 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), aims to develop a novel device for uterine hemostasis (stoppage of bleeding) after cesarean section procedures. The funded project seeks to finalize design parameters, validate materials, and conduct functional performance testing for this novel system, with the goal of enabling an early feasibility trial. Cesarean...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,052,276 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Lasarrus Clinic And Research Center Inc. The funding supports a 2-phase SBIR Fast-Track project to develop and validate a wearable multimodal sensor system for remote monitoring of chronic obstructive pulmonary disease (COPD) patients. The project aims to extend the awardee's patented "WearMe" platform to capture bilateral...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $162,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Connecticut. The grant will fund a 12-week proof-of-concept study testing a technology-delivered mindful walking intervention to reduce stress, increase physical activity, and lower blood pressure in Black women with hypertension. The project aims to address disparities in hypertension and physical activity rates among...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $585,794 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Tele-Stethoscope Inc., a small disadvantaged business, to develop a novel mobile phone technology for detecting preeclampsia and hypertension. The project aims to demonstrate proof-of-concept that ordinary mobile phones can reproduce physicians' diagnoses of preeclampsia and accurately measure blood pressure to detect hypertension. The...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $117,750 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the Ann & Robert H Lurie Children's Hospital of Chicago to develop and validate remote patient monitoring strategies for pediatric patients on invasive home mechanical ventilation (IHMV). The project aims to 1) validate the use of wireless biosensors and a portable capnograph to continuously collect physiologic data as an alternative to manual data...
This Project Grant award of $237,827 from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to develop a wearable optical device capable of continuous non-invasive arterial blood pressure monitoring in neonates. The award will fund the modification of the FlexNIRS device to measure pulsatile blood volume in newborns and test the device in 20 neonatal intensive care unit patients...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,847,271 Project Grant under CFDA 93.837 Cardiovascular Diseases Research to The Pennsylvania State University to develop a soft, stretchable, tissue-like bioadhesive electronic device for the long-term treatment of resistant hypertension. The project aims to create a minimally invasive device that can safely and effectively activate the carotid sinus baroreflex to reduce blood pressure in patients who are resistant to medication....
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $295,895 to Ricovr Healthcare Inc. to develop a rapid, low-cost, point-of-care (POC) diagnostic platform for quantitative measurement of placental growth factor (PlGF) to predict and detect pre-eclampsia. The goal is to create an objective, affordable POC tool to improve the clinical diagnosis and monitoring of pre-eclampsia, which...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $400,000 Project Grant to Electronic Biosciences, Inc. on Sep 20, 2024. The grant supports the development of an innovative analytical testing device to quantitatively characterize lipoprotein particles in blood. This technology will enable rapid, precise, and cost-effective measurement of lipoprotein size, concentration, and other physical properties, which are...
The federal Project Grant award R01HL175892, funded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and validate new technology for accurate, rapid, point-of-care, and high-frequency blood gas analysis. The $735,939 award supports two key objectives: 1) creating a miniaturized and automated device that attaches to an arterial catheter to enable direct sampling and immediate blood gas analysis at the bedside,...

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $639,165 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Washington University to develop an equitable and accessible wearable device for continuous calculation of blood loss for postpartum hemorrhage (PPH). The goal is to create a non-invasive sensor that can accurately monitor cardiovascular parameters and estimate blood loss, even with medical interventions, to enable early detection and treatment of PPH and reduce related maternal morbidity and mortality, particularly among Black women who face a 3x higher PPH-related death rate. The 5-year project will test the wearable sensor in a swine hemorrhage model and a diverse group of human subjects to validate its performance across skin tones and ensure it does not contribute to racial disparities in PPH management.

Generated 7/15/25, 10:41 AM